<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01148745</url>
  </required_header>
  <id_info>
    <org_study_id>DCI-0001</org_study_id>
    <nct_id>NCT01148745</nct_id>
  </id_info>
  <brief_title>Iron Indices and Intravenous Ferumoxytol: Time to Steady State</brief_title>
  <official_title>Iron Indices and Intravenous Ferumoxytol: Time to Steady State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dialysis Clinic, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dialysis Clinic, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the time point of transferrin saturation (TSAT) and
      ferritin stabilization after a thirteen-treatment period following a ferumoxytol load, as
      well as to determine the point at which serum ferritin and TSAT concentrations can be checked
      in iron deficiency anemia (IDA) hemodialysis patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Weeks Until Transferrin Saturation (TSAT) and Ferritin Stabilize</measure>
    <time_frame>pre-dosing/baseline, and 7 (visit 5), 14 (visit 8), 21 (visit 11) and 28 (visit 14) days after drug administration</time_frame>
    <description>TSAT,ferritin,and TIBC measured before start of dialysis on dosing days, and on next 13 HD treatments. Continuous variables were summarized using median. Paired continuous data (e.g., TSAT, serum ferritin) were compared using the Wilcoxon signed rank test. Analyses evaluating stabilization of post drug iron indices was determined by comparing consecutive values at consecutive dialysis sessions and when there was no longer a difference between 2 consecutive time points, levels were considered stabilized. P-values &lt;0.05 were considered statistically significant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transferrin Saturation (TSAT)</measure>
    <time_frame>7 (visit 5), 14 (visit 8), 21 (visit 11), and 28 (visit14) days.</time_frame>
    <description>Transferrin saturation (TSAT) measured as a percentage, is a medical laborastory test. It is the ratio of serum iron and total iron-binding capacity, multiplied by 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Ferritin</measure>
    <time_frame>7 (visit 5), 14 (visit 8), 21 (visit 11) and 28 days (visit 14)</time_frame>
    <description>Serum ferritin values were measured at all visits</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>ferumoxytol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FDA approved drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferumoxytol</intervention_name>
    <description>510 milligram (mg) intravenous (IV) injection (30 mg/second (sec) over 17 seconds) after at least one hour of hemodialysis (HD), second 510 mg IV injection administered at next consecutive dialysis treatment (3-5 days after first injection)</description>
    <arm_group_label>ferumoxytol</arm_group_label>
    <other_name>Feraheme</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hemodialysis subjects who have received dialysis treatment for more than 90
             days

          -  TSAT less than or equal to 25 percent

          -  Serum ferritin less than or equal to 200 nanograms/milliliter (ng/mL)

          -  (Female) Subjects are willing to use reliable contraception, or have undergone
             menopause (chemical or surgical)

          -  Subjects who are able to read and write in English

          -  Subjects who have signed consent

        Exclusion Criteria:

          -  Subjects who have been enrolled in a clinical trial within the past 30 days

          -  Subjects who have received IV iron within 4 weeks of the start of the study

          -  Serum ferritin greater than or equal to 1200 ng/dL

          -  Hemoglobin (Hb) less than 10 grams/deciliter (g/dL), or greater than 13.5 g/dL

          -  Evidence of iron overload

          -  Known hypersensitivity to ferumoxytol or any of its components

          -  Anemia caused by conditions other than iron deficiency

          -  Subjects with elective surgeries scheduled within the next 3 months

          -  Subjects with elective magnetic resonance procedure scheduled during the study period

          -  Subjects who have been hospitalized within the past 30 days (excluding vascular access
             care)

          -  Subjects who have received a blood transfusion in the past 30 days

          -  Subjects who are transfusion dependent

          -  (Female) Subjects who are pregnant or nursing

          -  Subjects with known inflammatory conditions which may affect serum ferritin

          -  Subjects who are considered to be clinically unstable at the discretion of Principal
             Investigator (P.I.)

          -  Subjects who have a clinically unstable blood pressure (BP) of systolic greater than
             180 millimeters of mercury (mmHg) and/or diastolic greater than 100 mmHg (sitting,
             pre-dialysis)

          -  Subjects with life expectancy less than 6 months

          -  Subjects who refuse to sign consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toros Kapoian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DCI North Brunswick</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dialysis Clinic, Inc.</name>
      <address>
        <city>North Brunswick</city>
        <state>New Jersey</state>
        <zip>08902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2010</study_first_submitted>
  <study_first_submitted_qc>June 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <results_first_submitted>July 19, 2011</results_first_submitted>
  <results_first_submitted_qc>March 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 30, 2012</results_first_posted>
  <last_update_submitted>March 28, 2012</last_update_submitted>
  <last_update_submitted_qc>March 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ferumoxytol</title>
          <description>2 doses of 510 mg IV over 17 seconds separated by 3 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ferumoxytol</title>
          <description>2 doses of 510 mg IV over 17 seconds separated by 3 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Weeks Until Transferrin Saturation (TSAT) and Ferritin Stabilize</title>
        <description>TSAT,ferritin,and TIBC measured before start of dialysis on dosing days, and on next 13 HD treatments. Continuous variables were summarized using median. Paired continuous data (e.g., TSAT, serum ferritin) were compared using the Wilcoxon signed rank test. Analyses evaluating stabilization of post drug iron indices was determined by comparing consecutive values at consecutive dialysis sessions and when there was no longer a difference between 2 consecutive time points, levels were considered stabilized. P-values &lt;0.05 were considered statistically significant.</description>
        <time_frame>pre-dosing/baseline, and 7 (visit 5), 14 (visit 8), 21 (visit 11) and 28 (visit 14) days after drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ferumoxytol</title>
            <description>All participants received 510 mg IV ferumoxytol at both visits 1 and 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Weeks Until Transferrin Saturation (TSAT) and Ferritin Stabilize</title>
          <description>TSAT,ferritin,and TIBC measured before start of dialysis on dosing days, and on next 13 HD treatments. Continuous variables were summarized using median. Paired continuous data (e.g., TSAT, serum ferritin) were compared using the Wilcoxon signed rank test. Analyses evaluating stabilization of post drug iron indices was determined by comparing consecutive values at consecutive dialysis sessions and when there was no longer a difference between 2 consecutive time points, levels were considered stabilized. P-values &lt;0.05 were considered statistically significant.</description>
          <units>weeks</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transferrin Saturation (TSAT)</title>
        <description>Transferrin saturation (TSAT) measured as a percentage, is a medical laborastory test. It is the ratio of serum iron and total iron-binding capacity, multiplied by 100</description>
        <time_frame>7 (visit 5), 14 (visit 8), 21 (visit 11), and 28 (visit14) days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ferumoxytol 510 mg</title>
            <description>2 doses of 510 mg IV over 17 seconds separated by 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Transferrin Saturation (TSAT)</title>
          <description>Transferrin saturation (TSAT) measured as a percentage, is a medical laborastory test. It is the ratio of serum iron and total iron-binding capacity, multiplied by 100</description>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TSAT at day 7 (visit 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" lower_limit="14.7" upper_limit="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSAT at day 14 (visit 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" lower_limit="14.7" upper_limit="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSAT at day 21 (visit 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" lower_limit="17.0" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSAT at day 28 (visit 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" lower_limit="15.2" upper_limit="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Ferritin</title>
        <description>Serum ferritin values were measured at all visits</description>
        <time_frame>7 (visit 5), 14 (visit 8), 21 (visit 11) and 28 days (visit 14)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ferumoxytol</title>
            <description>2 doses of 510 mg IV over 17 seconds separated by 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Ferritin</title>
          <description>Serum ferritin values were measured at all visits</description>
          <units>g/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ferritin at day 7 (visit 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="912" lower_limit="679" upper_limit="1257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ferritin at day 14 (visit 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="713" lower_limit="535" upper_limit="1236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ferritin at day 21 (visit 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="679" lower_limit="590" upper_limit="1257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ferritin at day 28 (visit 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="670" lower_limit="527" upper_limit="3172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ferumoxytol</title>
          <description>2 doses of 510 mg IV over 17 seconds separated by 3 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Toros Kapoian, M.D., F.A.C.P.</name_or_title>
      <organization>Dialysis Clinic, Inc.</organization>
      <phone>732-940-8368</phone>
      <email>Toros.Kapoian@dciinc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

